Amgen Inc. (AMGN) Scheduled to Post Earnings on Tuesday
Amgen Inc. (NASDAQ:AMGN) is scheduled to be releasing its earnings data after the market closes on Tuesday, July 25th. Analysts expect Amgen to post earnings of $3.10 per share for the quarter. Amgen has set its FY17 guidance at $12.00-12.60 EPS.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.00 by $0.15. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The firm had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the previous year, the company earned $2.90 earnings per share. The company’s quarterly revenue was down 1.1% on a year-over-year basis. On average, analysts expect Amgen to post $12.39 EPS for the current fiscal year and $12.62 EPS for the next fiscal year.
Amgen Inc. (AMGN) opened at 177.40 on Tuesday. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21. The firm has a 50 day moving average of $162.22 and a 200 day moving average of $162.64. The firm has a market capitalization of $130.46 billion, a P/E ratio of 16.85 and a beta of 1.35.
ILLEGAL ACTIVITY WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/07/18/amgen-inc-amgn-scheduled-to-post-earnings-on-tuesday.html.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by insiders.
A number of research firms have recently commented on AMGN. Mizuho set a $195.00 target price on Amgen and gave the stock a “buy” rating in a research note on Saturday, May 6th. UBS AG reiterated a “neutral” rating and set a $174.00 target price (down from $175.00) on shares of Amgen in a research note on Monday, May 22nd. Jefferies Group LLC reiterated a “buy” rating and set a $195.00 target price on shares of Amgen in a research note on Monday. Cowen and Company reiterated an “outperform” rating and set a $209.00 target price on shares of Amgen in a research note on Wednesday, April 19th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $198.00 target price (down from $200.00) on shares of Amgen in a research note on Monday, May 22nd. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have given a buy rating and three have assigned a strong buy rating to the company’s stock. Amgen has an average rating of “Buy” and a consensus price target of $185.17.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.